These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 8578831)

  • 1. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity.
    Kotloff KL; Nataro JP; Losonsky GA; Wasserman SS; Hale TL; Taylor DN; Sadoff JC; Levine MM
    Vaccine; 1995 Nov; 13(16):1488-94. PubMed ID: 8578831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2.
    Kotloff KL; Losonsky GA; Nataro JP; Wasserman SS; Hale TL; Taylor DN; Newland JW; Sadoff JC; Formal SB; Levine MM
    Vaccine; 1995 Apr; 13(5):495-502. PubMed ID: 7639017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.
    Talaat KR; Alaimo C; Martin P; Bourgeois AL; Dreyer AM; Kaminski RW; Porter CK; Chakraborty S; Clarkson KA; Brubaker J; Elwood D; Frölich R; DeNearing B; Weerts H; Feijoo BL; Halpern J; Sack D; Riddle MS; Fonck VG
    EBioMedicine; 2021 Apr; 66():103310. PubMed ID: 33862589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
    Robin G; Keisari Y; Slepon R; Ashkenazi S; Cohen D
    Vaccine; 1999 Aug; 17(23-24):3109-15. PubMed ID: 10462247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602.
    Coster TS; Hoge CW; VanDeVerg LL; Hartman AB; Oaks EV; Venkatesan MM; Cohen D; Robin G; Fontaine-Thompson A; Sansonetti PJ; Hale TL
    Infect Immun; 1999 Jul; 67(7):3437-43. PubMed ID: 10377124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a.
    Shim DH; Chang SY; Park SM; Jang H; Carbis R; Czerkinsky C; Uematsu S; Akira S; Kweon MN
    Vaccine; 2007 Jun; 25(25):4828-36. PubMed ID: 17507120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge.
    Tacket CO; Binion SB; Bostwick E; Losonsky G; Roy MJ; Edelman R
    Am J Trop Med Hyg; 1992 Sep; 47(3):276-83. PubMed ID: 1524140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Killed oral Shigella vaccine made from Shigella flexneri 2a protects against challenge in the rabbit model of shigellosis.
    Chakrabarti MK; Bhattacharya J; Bhattacharya MK; Nair GB; Bhattacharya SK; Mahalanabis D
    Acta Paediatr; 1999 Feb; 88(2):161-5. PubMed ID: 10102148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study.
    Shimanovich AA; Buskirk AD; Heine SJ; Blackwelder WC; Wahid R; Kotloff KL; Pasetti MF
    Clin Vaccine Immunol; 2017 Feb; 24(2):. PubMed ID: 27927680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model.
    Mallett CP; VanDeVerg L; Collins HH; Hale TL
    Vaccine; 1993; 11(2):190-6. PubMed ID: 8438617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccine.
    Clarkson KA; Talaat KR; Alaimo C; Martin P; Bourgeois AL; Dreyer A; Porter CK; Chakraborty S; Brubaker J; Elwood D; Frölich R; DeNearing B; Weerts HP; Feijoo B; Halpern J; Sack D; Riddle MS; Fonck VG; Kaminski RW
    EBioMedicine; 2021 Apr; 66():103308. PubMed ID: 33813141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and evaluation of a double mutant of Shigella flexneri as a candidate for oral vaccination against shigellosis.
    Sansonetti PJ; Arondel J
    Vaccine; 1989 Oct; 7(5):443-50. PubMed ID: 2683460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG.
    Kotloff KL; Noriega F; Losonsky GA; Sztein MB; Wasserman SS; Nataro JP; Levine MM
    Infect Immun; 1996 Nov; 64(11):4542-8. PubMed ID: 8890204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An auxotrophic live oral Shigella flexneri vaccine: development and testing.
    Kärnell A; Stocker BA; Katakura S; Sweiha H; Reinholt FP; Cam PD; Trach DD; Lindberg AA
    Rev Infect Dis; 1991; 13 Suppl 4():S357-61. PubMed ID: 2047663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New animal model of shigellosis in the Guinea pig: its usefulness for protective efficacy studies.
    Shim DH; Suzuki T; Chang SY; Park SM; Sansonetti PJ; Sasakawa C; Kweon MN
    J Immunol; 2007 Feb; 178(4):2476-82. PubMed ID: 17277155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity study of the auxotrophic Shigella flexneri 2a vaccine SFL1070 with a deleted aroD gene in adult Swedish volunteers.
    Kärnell A; Li A; Zhao CR; Karlsson K; Nguyen BM; Lindberg AA
    Vaccine; 1995 Jan; 13(1):88-99. PubMed ID: 7762285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shigellosis in custodial institutions. II. Clinical, immunologic and bacteriologic response of institutionalized children to oral attenuated shigella vaccines.
    Levine MM; Dupont HL; Gangarosa EJ; Hornick RB; Snyder MJ; Libonati JP; Glaser K; Formal SB
    Am J Epidemiol; 1972 Jul; 96(1):40-9. PubMed ID: 4557072
    [No Abstract]   [Full Text] [Related]  

  • 18. Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidates.
    Simon JK; Wahid R; Maciel M; Picking WL; Kotloff KL; Levine MM; Sztein MB
    Vaccine; 2009 Jan; 27(4):565-72. PubMed ID: 19022324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a multicomponent live, attenuated Shigella flexneri vaccine.
    DeLaine BC; Wu T; Grassel CL; Shimanovich A; Pasetti MF; Levine MM; Barry EM
    Pathog Dis; 2016 Jul; 74(5):. PubMed ID: 27106253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection of adult rabbits and monkeys from lethal shigellosis by oral immunization with a thymine-requiring and temperature-sensitive mutant of Shigella flexneri Y.
    Ahmed ZU; Sarker MR; Sack DA
    Vaccine; 1990 Apr; 8(2):153-8. PubMed ID: 2186582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.